You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNebivolol
Accession NumberDB04861
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionNebivolol is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription. [Wikipedia]
Structure
Thumb
Synonyms
1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
Narbivolol
Nebivololum
External Identifiers
  • PI-21858
  • R65,824
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BystolicTablet20 mg/1OralCardinal Health2008-01-22Not applicableUs
BystolicTablet2.5 mg/1OralForest Laboratories, Inc.2008-01-22Not applicableUs
BystolicTablet5 mg/1OralA S Medication Solutions2008-01-22Not applicableUs
BystolicTablet5.0 mgOralForest Laboratories Canada Inc2013-04-02Not applicableCanada
BystolicTablet5 mg/1OralPhysicians Total Care, Inc.2008-10-02Not applicableUs
BystolicTablet10 mg/1OralCardinal Health2008-01-22Not applicableUs
BystolicTablet5 mg/1OralForest Laboratories, Inc.2008-01-22Not applicableUs
BystolicTablet10 mg/1OralA S Medication Solutions2008-01-22Not applicableUs
BystolicTablet10.0 mgOralForest Laboratories Canada Inc2013-04-02Not applicableCanada
BystolicTablet10 mg/1OralPhysicians Total Care, Inc.2009-04-15Not applicableUs
BystolicTablet10 mg/1OralCarilion Materials Management2008-01-22Not applicableUs
BystolicTablet10 mg/1OralForest Laboratories, Inc.2008-01-22Not applicableUs
BystolicTablet5 mg/1OralA S Medication Solutions2008-01-22Not applicableUs
BystolicTablet20.0 mgOralForest Laboratories Canada Inc2013-04-02Not applicableCanada
BystolicTablet5 mg/1OralCardinal Health2008-01-22Not applicableUs
BystolicTablet2.5 mgOralForest Laboratories Canada Inc2013-04-02Not applicableCanada
BystolicTablet20 mg/1OralForest Laboratories, Inc.2008-01-22Not applicableUs
BystolicTablet5 mg/1OralAvera Mc Kennan Hospital2015-03-19Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NebivololTablet2.5 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet5 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet10 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet20 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LobivonNot Available
NebicardNot Available
NebiletNot Available
NebilongNot Available
NodonNot Available
NubetaNot Available
Brand mixtures
NameLabellerIngredients
ByvalsonAllergan, Inc
Salts
Name/CASStructureProperties
Nebivolol hydrochloride
152520-56-4
ThumbNot applicableDBSALT001027
Categories
UNII030Y90569U
CAS number118457-14-0
WeightAverage: 405.435
Monoisotopic: 405.175164703
Chemical FormulaC22H25F2NO4
InChI KeyKOHIRBRYDXPAMZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
IUPAC Name
1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino}ethan-1-ol
SMILES
OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2
Pharmacology
IndicationFor the treatment of essential hypertension.
Structured Indications
PharmacodynamicsNebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion.
Mechanism of actionNebivolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Related Articles
AbsorptionThe absorption of nebivolol is rapid and not affected by food.
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic (CYP2D6-mediated)

Route of eliminationNot Available
Half life10 hours
ClearanceNot Available
ToxicityThe most common signs and symptoms associated with nebivolol overdosage are bradycardia and hypotension. Other important adverse events reported with nebivolol overdose include cardiac failure, dizziness, hypoglycemia, fatigue and vomiting. Other adverse events associated with β-blocker overdose include bronchospasm and heart block. The largest known ingestion of nebivolol worldwide involved a patient who ingested up to 500 mg of nebivolol along with several 100 mg tablets of acetylsalicylic acid in a suicide attempt. The patient experienced hyperhydrosis, pallor, depressed level of consciousness, hypokinesia, hypotension, sinus bradycardia, hypoglycemia, hypokalemia, respiratory failure and vomiting. The patient recovered.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nebivolol Action PathwayDrug actionSMP00366
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nebivolol.Experimental
AbirateroneThe serum concentration of Nebivolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nebivolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nebivolol.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nebivolol is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nebivolol.Approved, Withdrawn
AmbrisentanNebivolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateNebivolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineNebivolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nebivolol.Approved
AminophyllineNebivolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nebivolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nebivolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Nebivolol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nebivolol.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nebivolol.Approved
ArbutamineNebivolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArformoterolNebivolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nebivolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Nebivolol can be increased when it is combined with Artemether.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nebivolol.Approved
AtomoxetineThe serum concentration of Nebivolol can be increased when it is combined with Atomoxetine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nebivolol is combined with Azilsartan medoxomil.Approved
BambuterolNebivolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Nebivolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Nebivolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nebivolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nebivolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nebivolol.Withdrawn
Benzylpenicilloyl PolylysineNebivolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBepridil may increase the hypotensive activities of Nebivolol.Approved, Withdrawn
BeractantNebivolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe serum concentration of Nebivolol can be increased when it is combined with Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Nebivolol.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nebivolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Nebivolol is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Nebivolol.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Nebivolol.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nebivolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nebivolol.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Nebivolol.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Nebivolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nebivolol.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Bupivacaine.Approved, Investigational
BupranololNebivolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe serum concentration of Nebivolol can be increased when it is combined with Bupropion.Approved
CabergolineCabergoline may increase the hypertensive activities of Nebivolol.Approved
CalfactantNebivolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nebivolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Nebivolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nebivolol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nebivolol.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nebivolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nebivolol.Approved, Investigational
CelecoxibThe serum concentration of Nebivolol can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololNebivolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibNebivolol may increase the bradycardic activities of Ceritinib.Approved
ChloroquineThe serum concentration of Nebivolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nebivolol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Nebivolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nebivolol.Approved
CholecalciferolThe serum concentration of Nebivolol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nebivolol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Nebivolol can be increased when it is combined with Cinacalcet.Approved
CitalopramThe serum concentration of Nebivolol can be increased when it is combined with Citalopram.Approved
ClemastineThe serum concentration of Nebivolol can be increased when it is combined with Clemastine.Approved
ClenbuterolNebivolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Nebivolol can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe serum concentration of Nebivolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nebivolol.Approved
ClotrimazoleThe serum concentration of Nebivolol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Nebivolol can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Nebivolol can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Nebivolol can be increased when it is combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Nebivolol is combined with Conivaptan.Approved, Investigational
CrizotinibNebivolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nebivolol.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nebivolol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.Approved
DarifenacinThe serum concentration of Nebivolol can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nebivolol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Nebivolol.Approved
DelavirdineThe serum concentration of Nebivolol can be increased when it is combined with Delavirdine.Approved
DeserpidineNebivolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nebivolol is combined with Desflurane.Approved
DesipramineThe serum concentration of Nebivolol can be increased when it is combined with Desipramine.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Nebivolol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nebivolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nebivolol.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nebivolol.Approved
DigoxinDigoxin may increase the bradycardic activities of Nebivolol.Approved
DihydralazineNebivolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Nebivolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nebivolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.Approved
DiphenhydramineThe serum concentration of Nebivolol can be increased when it is combined with Diphenhydramine.Approved
DipivefrinNebivolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nebivolol.Approved
DobutamineNebivolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Nebivolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nebivolol.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nebivolol.Approved
DronedaroneThe serum concentration of Nebivolol can be increased when it is combined with Dronedarone.Approved
DroxidopaNebivolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineThe serum concentration of Nebivolol can be increased when it is combined with Duloxetine.Approved
DyphyllineNebivolol may decrease the bronchodilatory activities of Dyphylline.Approved
EfonidipineNebivolol may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe serum concentration of Nebivolol can be increased when it is combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nebivolol.Approved, Vet Approved
EnalaprilatNebivolol may increase the hypotensive activities of Enalaprilat.Approved
EphedraNebivolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineNebivolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nebivolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Nebivolol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nebivolol.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Nebivolol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Nebivolol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Nebivolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nebivolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nebivolol.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Nebivolol.Approved
FenoterolNebivolol may decrease the bronchodilatory activities of Fenoterol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nebivolol is combined with Fimasartan.Approved
FingolimodNebivolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FluoxetineThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolNebivolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nebivolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Nebivolol.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Nebivolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nebivolol.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Nebivolol.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nebivolol.Approved, Investigational
HaloperidolThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Nebivolol is combined with Halothane.Approved, Vet Approved
HexamethoniumNebivolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nebivolol.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nebivolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nebivolol.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nebivolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nebivolol.Approved
IloprostIloprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Nebivolol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Nebivolol can be increased when it is combined with Imipramine.Approved
IndacaterolNebivolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nebivolol.Approved
IndenololNebivolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nebivolol can be increased when it is combined with Indinavir.Approved
IndoraminNebivolol may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nebivolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nebivolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nebivolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nebivolol.Approved
IsoetarineNebivolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nebivolol is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe serum concentration of Nebivolol can be increased when it is combined with Isoniazid.Approved
IsoprenalineNebivolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nebivolol.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nebivolol.Approved
IvabradineNebivolol may increase the bradycardic activities of Ivabradine.Approved
KetanserinNebivolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Nebivolol can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nebivolol.Approved
LacidipineNebivolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideNebivolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideNebivolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nebivolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Levobupivacaine.Approved
LevodopaNebivolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Nebivolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nebivolol is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nebivolol.Approved, Investigational
LofexidineNebivolol may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Nebivolol can be increased when it is combined with Lopinavir.Approved
LorcaserinThe serum concentration of Nebivolol can be increased when it is combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nebivolol.Approved
LucinactantNebivolol may increase the bradycardic activities of Lucinactant.Approved
LumefantrineThe serum concentration of Nebivolol can be increased when it is combined with Lumefantrine.Approved
MacitentanNebivolol may increase the hypotensive activities of Macitentan.Approved
ManidipineNebivolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nebivolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nebivolol.Approved
MethadoneThe serum concentration of Nebivolol can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nebivolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nebivolol.Approved
MethotrimeprazineThe serum concentration of Nebivolol can be increased when it is combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nebivolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nebivolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nebivolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nebivolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol.Approved
MetoprololThe serum concentration of Nebivolol can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineNebivolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Nebivolol.Withdrawn
MilnacipranMilnacipran may increase the tachycardic activities of Nebivolol.Approved
MinaprineMinaprine may increase the hypotensive activities of Nebivolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nebivolol.Approved
MirabegronThe serum concentration of Nebivolol can be increased when it is combined with Mirabegron.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nebivolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nebivolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nebivolol.Approved
MorphineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Morphine.Approved, Investigational
MoxonidineNebivolol may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nebivolol.Approved
NaftopidilNebivolol may increase the hypotensive activities of Naftopidil.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nesiritide.Approved, Investigational
NevirapineThe serum concentration of Nebivolol can be increased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nebivolol.Withdrawn
NicardipineThe serum concentration of Nebivolol can be increased when it is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nebivolol.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nebivolol.Approved
NiguldipineNebivolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nebivolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNebivolol may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nebivolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nebivolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Nebivolol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nebivolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nebivolol.Approved
NorepinephrineNebivolol may decrease the bronchodilatory activities of Norepinephrine.Approved
ObinutuzumabNebivolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nebivolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Nebivolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nebivolol.Approved, Investigational
OlodaterolNebivolol may decrease the bronchodilatory activities of Olodaterol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Nebivolol.Investigational
OrciprenalineNebivolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OxprenololOxprenolol may increase the hypotensive activities of Nebivolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nebivolol is combined with Paclitaxel.Approved, Vet Approved
PanobinostatThe serum concentration of Nebivolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.Approved
PargylinePargyline may increase the hypotensive activities of Nebivolol.Approved
ParoxetineThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideNebivolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Nebivolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Nebivolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nebivolol.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nebivolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nebivolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nebivolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nebivolol.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nebivolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nebivolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nebivolol.Approved
PhenylpropanolamineNebivolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilNebivolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nebivolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nebivolol is combined with Pipamperone.Approved
PirbuterolNebivolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Nebivolol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nebivolol.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Nebivolol.Approved
Poractant alfaNebivolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nebivolol is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nebivolol.Approved
PrimidonePrimidone may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ProcaterolNebivolol may decrease the bronchodilatory activities of Procaterol.Approved
PromazineThe serum concentration of Nebivolol can be increased when it is combined with Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the bradycardic activities of Nebivolol.Approved
PropofolThe risk or severity of adverse effects can be increased when Nebivolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nebivolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nebivolol.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nebivolol.Approved, Investigational
QuinidineThe serum concentration of Nebivolol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Nebivolol can be increased when it is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nebivolol.Approved
RanolazineThe serum concentration of Nebivolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Nebivolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nebivolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nebivolol.Approved
RescinnamineNebivolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nebivolol.Approved
RilmenidineNebivolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nebivolol is combined with Riociguat.Approved
RisperidoneNebivolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineNebivolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe serum concentration of Nebivolol can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabNebivolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Nebivolol.Approved, Investigational
RolapitantThe serum concentration of Nebivolol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Nebivolol can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Nebivolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nebivolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nebivolol.Withdrawn
SalbutamolNebivolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalmeterolNebivolol may decrease the bronchodilatory activities of Salmeterol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Nebivolol.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nebivolol.Approved, Investigational, Vet Approved
SelexipagNebivolol may increase the hypotensive activities of Selexipag.Approved
SertralineThe serum concentration of Nebivolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nebivolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Nebivolol.Approved
SitaxentanNebivolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nebivolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nebivolol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Nebivolol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Nebivolol.Approved
StiripentolThe serum concentration of Nebivolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nebivolol is combined with Streptokinase.Approved
SufentanilSufentanil may increase the bradycardic activities of Nebivolol.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nebivolol.Approved, Investigational
TemocaprilNebivolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Nebivolol.Approved
TerbinafineThe serum concentration of Nebivolol can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineNebivolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Nebivolol.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineNebivolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ThioridazineThe serum concentration of Nebivolol can be increased when it is combined with Thioridazine.Approved
TiboloneNebivolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe serum concentration of Nebivolol can be increased when it is combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Nebivolol.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nebivolol.Approved
TipranavirThe serum concentration of Nebivolol can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nebivolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Nebivolol.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nebivolol is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Nebivolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nebivolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nebivolol.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nebivolol.Experimental
TranylcypromineThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nebivolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nebivolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TrimazosinNebivolol may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nebivolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
UnoprostoneNebivolol may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nebivolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nebivolol.Approved
VenlafaxineThe serum concentration of Nebivolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.Approved
VilanterolNebivolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinpocetineNebivolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineNebivolol may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
ZiprasidoneThe serum concentration of Nebivolol can be increased when it is combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Thomas Bader, Alfred Stutz, Harald Hofmeier, Hans-Ulrich Bichsel, “Process for preparation of racemic Nebivolol.” U.S. Patent US20070149612, issued June 28, 2007.

US20070149612
General References
  1. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. [PubMed:16961165 ]
External Links
ATC CodesC07FB12C07AB12C07BB12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (69.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8483
Blood Brain Barrier+0.7802
Caco-2 permeable-0.5549
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor INon-inhibitor0.7443
P-glycoprotein inhibitor IINon-inhibitor0.567
Renal organic cation transporterNon-inhibitor0.8016
CYP450 2C9 substrateNon-substrate0.8738
CYP450 2D6 substrateNon-substrate0.7248
CYP450 3A4 substrateNon-substrate0.6822
CYP450 1A2 substrateInhibitor0.5145
CYP450 2C9 inhibitorNon-inhibitor0.7876
CYP450 2D6 inhibitorNon-inhibitor0.5994
CYP450 2C19 inhibitorNon-inhibitor0.5923
CYP450 3A4 inhibitorNon-inhibitor0.9441
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8336
Ames testNon AMES toxic0.7132
CarcinogenicityNon-carcinogens0.9402
BiodegradationNot ready biodegradable0.9953
Rat acute toxicity2.7228 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5769
hERG inhibition (predictor II)Inhibitor0.8381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral10.0 mg
TabletOral2.5 mg/1
TabletOral2.5 mg
TabletOral20 mg/1
TabletOral20.0 mg
TabletOral5 mg/1
TabletOral5.0 mg
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Bystolic 10 mg tablet2.09USD tablet
Bystolic 20 mg tablet2.09USD tablet
Bystolic 2.5 mg tablet2.06USD tablet
Bystolic 5 mg tablet2.06USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5759580 No1995-06-022015-06-02Us
US6545040 No2001-12-172021-12-17Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.44ALOGPS
logP3.21ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.52ChemAxon
pKa (Strongest Basic)8.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.32 m3·mol-1ChemAxon
Polarizability41.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzopyrans
Sub Class1-benzopyrans
Direct Parent1-benzopyrans
Alternative Parents
Substituents
  • 1-benzopyran
  • Aralkylamine
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Aryl halide
  • Aryl fluoride
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Oxacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. [PubMed:16961165 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. de Boer RA, Voors AA, van Veldhuisen DJ: Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007 Jul;8(10):1539-50. [PubMed:17661735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Nuttall SL, Routledge HC, Kendall MJ: A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. [PubMed:12795776 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on October 19, 2007 15:00 / Updated on December 07, 2016 02:38